Lymphodepletion with chemotherapy is typically carried out before administering cell therapies to ensure the cells can proliferate. Michael Nishimura, PhD, Loyola University Chicago, Chicago, IL, discusses strategies to boost the efficacy of cancer vaccines. Whilst lymphodepletion can suppress the activity of immune cells such as regulatory T cells (Tregs) and myeloid-derived suppressor cells, immune checkpoint inhibitors may be more suitable to complement the activity of vaccines. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
